G
064800
vs
K
KOSPI 200
Over the past 12 months, GemVaxLink Co Ltd has underperformed KOSPI 200, delivering a return of -42% compared to KOSPI 200's +150% growth.
Stocks Performance
064800 vs KOSPI 200
Performance Gap
064800 vs KOSPI 200
Performance By Year
064800 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GemVaxLink Co Ltd
Glance View
GemVaxLink is a South Korean biotech company that develops experimental medicines and related healthcare products. Its best-known work is in disease areas like cancer and brain disorders, where it studies its own drug candidates and works with research and clinical partners to move them forward. The company is not a mass drug manufacturer; it focuses on creating and testing new therapies and building value around those assets. It makes money in a few ways: by selling any products it has commercialized, by licensing drug rights, and by receiving payments tied to research and development partnerships. Its main customers and counterparties are usually hospitals, distributors, and pharmaceutical or biotech partners rather than everyday consumers. In this kind of business, the real product is often the intellectual property and clinical progress behind a drug candidate. What makes GemVaxLink different is that its value depends on the success of a small number of scientific programs, not on a wide catalog of steady consumer products. That gives it a higher-risk, more event-driven business model than a typical manufacturer. For investors, it is best understood as a development-stage life sciences company that tries to turn laboratory research into licensed therapies and commercial medical products.
